CaboRISE: A Phase II Study Evaluating Reduced Starting Dose and Dose Escalation of Cabozantinib As Second-Line Therapy for Advanced HCC in Patients with Compensated Liver Cirrhosis.
JOURNAL OF CLINICAL ONCOLOGY（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined